ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.557,27
-0,48%
S&P 500
5.346,99
-0,11%
Dow Jones
38.798,99
-0,22%
Euro vs US Dollar
1,0804
0,00%
Bitcoin
69.462,84
0,23%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) News

CYTO

Altamira Therapeutics (CYTO)

Altamira Therapeutics Ltd
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:CYTO
DatumZeitQuelleÜberschriftSymbolFirma
28/05/202416h31GlobeNewswire Inc.Altamira Therapeutics Provides Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
23/05/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy JournalNASDAQ:CYTOAltamira Therapeutics Ltd
16/05/202422h15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
01/05/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and InflammationNASDAQ:CYTOAltamira Therapeutics Ltd
24/04/202414h47GlobeNewswire Inc.Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
10/04/202414h00GlobeNewswire Inc.Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial ResultsNASDAQ:CYTOAltamira Therapeutics Ltd
04/04/202414h45GlobeNewswire Inc.Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024NASDAQ:CYTOAltamira Therapeutics Ltd
25/03/202413h47GlobeNewswire Inc.Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA VaccinesNASDAQ:CYTOAltamira Therapeutics Ltd
07/02/202414h47GlobeNewswire Inc.Altamira Therapeutics’ Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed JournalNASDAQ:CYTOAltamira Therapeutics Ltd
24/01/202414h47GlobeNewswire Inc.Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer TreatmentNASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202423h02Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:CYTOAltamira Therapeutics Ltd
22/01/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202422h45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202422h40Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CYTOAltamira Therapeutics Ltd
19/01/202422h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
08/01/202423h02Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:CYTOAltamira Therapeutics Ltd
08/01/202414h47GlobeNewswire Inc.Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics SummitNASDAQ:CYTOAltamira Therapeutics Ltd
29/12/202314h47GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202314h01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
11/12/202314h00GlobeNewswire Inc.Altamira Therapeutics Provides Investor and Business UpdateNASDAQ:CYTOAltamira Therapeutics Ltd
08/12/202315h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
05/12/202318h54GlobeNewswire Inc.Altamira Therapeutics to Host Investor & Business Update Call on December 11thNASDAQ:CYTOAltamira Therapeutics Ltd
29/11/202316h20GlobeNewswire Inc.Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity RequirementNASDAQ:CYTOAltamira Therapeutics Ltd
22/11/202322h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
21/11/202314h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
17/11/202315h04GlobeNewswire Inc.Altamira Therapeutics Announces Partial Spin-Off of Bentrio® BusinessNASDAQ:CYTOAltamira Therapeutics Ltd
10/11/202314h47GlobeNewswire Inc.Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal BetahistineNASDAQ:CYTOAltamira Therapeutics Ltd
31/10/202321h30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
04/10/202315h00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:CYTOAltamira Therapeutics Ltd
 Showing the most relevant articles for your search:NASDAQ:CYTO

Kürzlich von Ihnen besucht

NASDAQ
MSFT
Microsoft
TG
MBG
MercedesBenz
NYSE
MRK
Merck
NYSE
XOM
Exxon Mobil
TG
TUI1
Tui
FX
EURGBP
Euro vs Sterling
COIN
BTCUSD
Bitcoin
NYSE
NKE
Nike
TG
432
Arbor Metals
NASDAQ
TSLA
Tesla
COIN
SOLUSD
Solana
AMEX
XLV
Health Care Select Sector
USOTC
BASFY
BASF (QX)
PM
XAUUSD
Gold vs US Dollar
USOTC
DTEGY
Deutsche Telekom (QX)
TG
D7G
Nel ASA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten